Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cyclin-dependent kinase 3 | Starlite/ChEMBL | References |
Homo sapiens | cyclin-dependent kinase 4 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | cyclin-dependent kinase 3 | 305 aa | 303 aa | 32.0 % |
Trypanosoma brucei | mitogen-activated protein kinase 5 | cyclin-dependent kinase 4 | 303 aa | 312 aa | 29.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | CMGC family protein kinase | 0.0053 | 0.0142 | 0.5 |
Trypanosoma brucei | cdc2-related kinase 3 | 0.0053 | 0.0142 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.0053 | 0.0142 | 0.5 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0053 | 0.0142 | 1 |
Echinococcus multilocularis | glutamate receptor NMDA | 0.0078 | 0.3345 | 0.3289 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0085 | 0.4302 | 0.422 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0053 | 0.0142 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0085 | 0.4302 | 0.4255 |
Trypanosoma brucei | cdc2-related kinase 1 | 0.0053 | 0.0142 | 0.5 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.0053 | 0.0142 | 0.5 |
Giardia lamblia | Kinase, CMGC CDK | 0.0053 | 0.0142 | 0.5 |
Schistosoma mansoni | glutamate receptor NMDA | 0.01 | 0.617 | 1 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0053 | 0.0142 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.013 | 1 | 1 |
Loa Loa (eye worm) | CMGC/CDK/CDK5 protein kinase | 0.0053 | 0.0142 | 1 |
Trypanosoma cruzi | cdc2-related kinase 1 | 0.0053 | 0.0142 | 0.5 |
Leishmania major | cell division related protein kinase 2,cdc2-related kinase | 0.0053 | 0.0142 | 0.5 |
Echinococcus multilocularis | cyclin dependent kinase 5 | 0.0053 | 0.0142 | 0.006 |
Toxoplasma gondii | cell-cycle-associated protein kinase CDK, putative | 0.0053 | 0.0142 | 0.5 |
Echinococcus granulosus | glutamate receptor NMDA | 0.0078 | 0.3345 | 0.3249 |
Brugia malayi | cell division control protein 2 homolog | 0.0053 | 0.0142 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0053 | 0.0142 | 0.5 |
Plasmodium vivax | protein kinase Crk2 | 0.0053 | 0.0142 | 0.5 |
Brugia malayi | Protein kinase domain containing protein | 0.0053 | 0.0142 | 0.5 |
Echinococcus multilocularis | cyclin dependent kinase | 0.0053 | 0.0142 | 0.006 |
Plasmodium falciparum | protein kinase 5 | 0.0053 | 0.0142 | 0.5 |
Entamoeba histolytica | cell division protein kinase 2, putative | 0.0053 | 0.0142 | 0.5 |
Echinococcus multilocularis | cyclin dependent kinase 1 | 0.0053 | 0.0142 | 0.006 |
Leishmania major | cell division protein kinase 2,cdc2-related kinase | 0.0053 | 0.0142 | 0.5 |
Echinococcus multilocularis | cyclin dependent kinase 1 | 0.0053 | 0.0142 | 0.006 |
Giardia lamblia | Kinase, CMGC CDK | 0.0053 | 0.0142 | 0.5 |
Loa Loa (eye worm) | CMGC/CDK/CDC2 protein kinase | 0.0053 | 0.0142 | 1 |
Trypanosoma cruzi | cdc2-related kinase 3 | 0.0053 | 0.0142 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 26 nM | Inhibitory activity against Cyclin-dependent kinase 2 (CDK2) | ChEMBL. | 15546737 |
IC50 (binding) | = 26 nM | Inhibitory activity against Cyclin-dependent kinase 2 (CDK2) | ChEMBL. | 15546737 |
IC50 (binding) | = 105 nM | Inhibitory activity against Cyclin-dependent kinase 1 (CDK1) | ChEMBL. | 15546737 |
IC50 (binding) | = 786 nM | Inhibitory activity against Cyclin-dependent kinase 4 (CDK4) | ChEMBL. | 15546737 |
IC50 (binding) | = 786 nM | Inhibitory activity against Cyclin-dependent kinase 4 (CDK4) | ChEMBL. | 15546737 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.